Study Type
Interventional-Drug
ongoing
REVIVE is an international multi-centre trial to evaluate azithromycin prophylaxis to reduce excess mortality among people with advanced HIV disease and CD4 count of 100 cells/mm3 or less.
Azithromycin, provided for 4 weeks together with antiretroviral therapy, will be compared with matching placebo and given on a background of standard of care for advanced HIV disease, as determined by relevant local guidelines.
Primary outcome:
All-cause mortality at 24 weeks after randomization
Secondary outcomes:
• All-cause mortality at 12 weeks
• Hospitalization at 24 weeks
• Composite of hospitalization and all-cause mortality at 24 weeks
Sub-studies will evaluate additional outcomes of interest including cause of death and carriage of antimicrobial resistant pathogens, as well cost-effectiveness of azithromycin.
For inquiries about the REVIVE study, please don’t hesitate to reach out to the research team at revive@phri.ca.
REVIVE design and countriesStudy Design
Double blinded, placebo-controlled
NO. of Countries
6 (vanguard); 13 (main trial)
NO. of Sites
20 (vanguard); 150 (main trial)
NO. of Participants
8000
Study Period
2023-2026
Sponsor
Population Health Research Institute
John Eikelboom
Senior Scientist
John Eikelboom
Senior Scientist
John Eikelboom is Professor, Department of Medicine, McMaster University, Senior Scientist, Population Health Research Institute, Hamilton Health Sciences Corporation, and Hematologist, Thrombosis Service, Hamilton General Hospital. He completed training in Internal Medicine and Hematology in Perth, Australia, in 1998 and in Health Research Methodology at McMaster University, Canada, in 2000.
He has authored or co-authored more than 800 articles in peer-reviewed journals and for the past decade has been listed annually by the Web of Science among the top 1% of cited researchers. He holds the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis. His current research, supported by peer reviewed funding from the Canadian Institutes for Health Research and the Gates Foundation focuses on the efficacy and safety of antithrombotic therapies in arterial, venous, cardiac, and procedure-associated thromboembolism as well as strategies to reduce the burden of the “big three” infectious diseases (HIV, TB, malaria) on the African continent.
Thomas Scheier
Investigator
Thomas Scheier
Investigator
Thomas Scheier, an infectious diseases physician, is a MSc student in the Health Research Methodology Program at McMaster University (supervised by Associate PHRI Scientist Dominik Mertz).
His research interests include antimicrobial resistance, infection control, and hospital epidemiology. Supervised by PHRI Senior Scientist John Eikelboom, he is project officer of the REVIVE trial.
Sumathy Rangarajan
Program Director
Sumathy Rangarajan
Program Director
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
